FGF401

Overview

FGF401 is a selective, non-covalent FGFR4 (FGFR4) inhibitor under investigation in hepatocellular carcinoma (HCC) enriched for FGF19 expression. Like BLU-554, FGF401 requires FGF19 protein expression (by IHC) as an enrollment biomarker, exploiting FGF19–FGFR4 axis dependence in a subset of HCCs.

Evidence in the corpus

• Cited alongside BLU-554 and H3B-6527 as an FGFR4 inhibitor requiring FGF19 IHC expression for biomarker-driven enrichment in HCC; FGF19 amplification occurs in ~5–10% of HCCs PMID:24798001.

Resistance mechanisms

Cancer types (linked)

• HCC

Sources

This page was processed by entity-page-writer on 2026-05-11.